NCT03819465Active, not recruitingPhase 1
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 175 (actual)
- First submitted
- 13 Dec 2018
- Start date
- 27 Dec 2018
- Primary completion date
- 23 May 2023
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT03819465
- EU CT number
- 2024-511956-42-00
- EudraCT number
- 2018-001748-74
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 175
- From 27 Dec 2018 to the primary completion date, 23 May 2023
- 24 sites in 9 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active or prior documented autoimmune or inflammatory disorders
- Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
Other illness
- History of active primary immunodeficiency
Other
- Untreated CNS metastases
Who the study is looking for
- Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
- No prior chemotherapy or any other systemic therapy for metastatic NSCLC
- Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy
- Known tumor PD-L1 status
- Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
- WHO/ECOG status at 0 or 1 at enrollment
- Life expectancy of at least 12 weeks
- Troponin I or T ≤ ULN (per institutional guidelines)
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (24)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.